Psoriasis in pregnant women

Albanova V.I.; Petrova S.Yu.

doi:https://doi.org/10.17116/klinderma202423051517

Close metadata

Recommended articles:

Dynamics of Substance P and Filaggrin Levels on Combined Treatment of Atopic Dermatitis with Emollient and Topical Antipruritic Drug in Pregnant Women. Russian Journal of Clinical Dermatology and Venereology. 2024;(6):662-666

Black Acanthosis: Diagnosis and Treatment Issues. Russian Journal of Clinical Dermatology and Venereology. 2024;(6):709-712

Comparative analysis of the results of treatment of gastric polyps by methods of loop electroexcision, laser and endoscopic polypectomy with aspiration capture. Endoscopic Surgery. 2024;(6):24-30

Peculiarities of placental microRNA expression in patients with preeclampsia and fetal growth restriction. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):14-25

Changes in the type of psychological component of the gestational dominant in pregnant women in the third trimester after completing the perinatal preparation program. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):66-71

Sexual function of women during pregnancy. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):112-117

Immunomodulatory therapy in the postoperative period in chronic purulent otitis media. Russian Bulletin of Otorhinolaryngology. 2024;(6):10-17

Antifungal immunity in patients with chronic rhinosinusitis with nasal polyps. Russian Bulletin of Otorhinolaryngology. 2024;(6):40-45

Functional cytokine redundancy in pregnancy. Russian Journal of Human Reproduction. 2024;(6):73-80

Clinical case of successful pregnancy in a patient with ectopic ACTH syndrome after radical surgical treatment. Russian Journal of Human Reproduction. 2024;(6):118-123

Abstract:

Psoriasis is a chronic skin disease. There is no clear opinion on psoriasis course in pregnant women in literature. Many women have stabilization and improvement of state, but not all. Remission and improvement of psoriasis course are possible due to pregnant women endocrine profile. Chorionic gonadotropin, progesterone, estradiol and placental lactogen modify the mother’s immune response from Th1 inflammatory cytokines pattern to Th2 pattern. The influence of Th17 is also decreasing. Meanwhile, psoriasis exacerbation can occur at any period of pregnancy. Its main causes are the progression of metabolic syndrome and insulin resistance, psycho-emotional stress, gastrointestinal tract activity disorder, toxicoses and gestoses. Treatment options for pregnant women are limited due to unethical issues of conducting clinical trials. It’s safe to use topical glucocorticoids, narrow-band UVB equal 311 nm, moisturizing and peeling products based on 30—50% of urea, zinc preparations (0.2% zinc pyrithione). Cyclosporine and systemic glucocorticoids are recommended to use as a systemic therapy in case of severe course. There are studies on the safety of applying some types of biological drugs in pregnant women with sufficient evidence base.

Keywords:

psoriasis

pregnancy

peeling products

treatment

immune system

Authors:

Albanova V.I.

Vladimirsky Moscow Regional Research Clinical Institute

ORCID: 0000-0001-8688-7578

Petrova S.Yu.

Mechnikov Research Institute of Vaccines and Sera;
Retinoids JSC

ORCID: 0000-0003-3034-0148

Received:

08.07.2024

Accepted:

22.07.2024

Close metadata

References:

Simionescu AA, Danciu BM, Stanescu AMA. State-of-the-Art Review of Pregnancy-Related Psoriasis. Medicina (Kaunas). 2021;57(8):804. https://doi.org/10.3390/medicina57080804
Romasheva ZhZh. Gender characteristics of behavior in stressful situations. Nauchnye issledovaniya. 2016;4(5):1-2. (In Russ.).
Klinicheskie rekomendatsii. Psoriaz (L40). Ministerstvo zdravookhraneniya Rossijskoj Federatsii. (In Russ.). Accessed July 08, 2024. https://diseases.medelement.com/disease/%D0%BF%D1%81%D0%BE%D1%80%D0%B8%D0%B0%D0%B7-%D0%BA%D1%80-%D1%80%D1%84-2023/17540
Dand N, Mahil SK, Capon F, Smith CH, Simpson MA, Barker JN. Psoriasis and Genetics. Acta Derm Venereol. 2020;100(3):adv00030. https://doi.org/10.2340/00015555-3384
Tokuyama M, Mabuchi T. New Treatment Addressing the Pathogenesis of Psoriasis. Int J Mol Sci. 2020;21(20):7488. https://doi.org/10.3390/ijms21207488
Owczarek W, Walecka I, Lesiak A, Czajkowski R, Reich A, Zerda I, Narbutt J. The Use of Biological Drugs in Psoriasis Patients Prior to Pregnancy, During Pregnancy and Lactation: A Review of Current Clinical Guidelines. Postepy Dermatol Alergol. 2020;37(6):821-830. https://doi.org/10.5114/ada.2020.102089
Raychaudhuri SP, Navare T, Gross J, Raychaudhuri SK. Clinical Course of Psoriasis During Pregnancy. Int J Dermatol. 2003;42(7):518-520. https://doi.org/10.1046/j.1365-4362.2003.01760.x
Murase JE, Chan KK, Garite TJ, Cooper DM, Weinstein GD. Hormonal Effect on Psoriasis in Pregnancy and Postpartum. Arch Dermatol. 2005; 141(5):601-606. https://doi.org/10.1001/archderm.141.5.601
Boyd AS, Morris LF, Phillips CM, Menter MA. Psoriasis and Pregnancy: Hormone and Immune System Interaction. Int J Dermatol. 1996;35(3): 169-172. https://doi.org/10.1111/j.1365-4362.1996.tb01632.x
Gudjonsson JE, Karason A, Runarsdottir EH, Antonsdottir AA, Hauksson VB, Jónsson HH, Gulcher J, Stefansson K, Valdimarsson H. Distinct Clinical Differences between HLA-Cw*0602 Positive and Negative Psoriasis Patients — An Analysis of 1019 HLA-C- and HLA-B-typed Patients. J Invest Dermatol. 2006;126(4):740-745. https://doi.org/10.1038/sj.jid.5700118
Zhang P, Su Y, Li S, Chen H, Wu R, Wu H. The Roles of T Cells in Psoriasis. Front. Immunol. 2023;14:1081256. https://doi.org/10.3389/fimmu.2023.1081256
Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4+ Effector T Cells Develop via a Lineage Distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123-1132.
Cerni C, Tatra G, Bohn H. Immunosuppression by Human Placenta Lactogen (HPL) and the Pregnancy-specific beta 1-glycoprotein (SP-1). Inhibition of Mitogen-induced Lymphocyte Transformation. Arch Gynakol. 1977;223(1):1-7. https://doi.org/10.1007/BF00675078
Piccinni MP, Raghupathy R, Saito S, Szekeres-Bartho J. Cytokines, Hormones and Cellular Regulatory Mechanisms Favoring Successful Reproduction. Front Immunol. 2021;12:717808. https://doi.org/10.3389/fimmu.2021.717808
Zabarovskaya ZV. Narushenie uglevodnogo obmena vo vremya beremennosti: monografiya v 2 ch. Minsk: BSMU; 2010. (In Russ.).
Albanova VI, Petrova SYu. Features of Management of Atopic Dermatitis in Pregnant Women. Vestnik dermatologii i venerologii. 2023;99(5):29-40. (In Russ.). https://doi.org/10.25208/vdv13279
Shirshev SV, Zamorina SA. The role of Chorionic Gonadotropin in the Formation of Immunological Tolerance During Pregnancy. Problems of Endocrinology. 2023;99(5):29-40. (In Russ.).
Spravochnik po akusherstvu i ginekologii. Savelyeva GM, ed. M.: Meditsina; 1992. (In Russ.).
Osayande O, Ekpruke C. Serum Cortisol Levels in Pregnancy and Six Weeks Post-Partum. African Scientist. 2017;18(4):235-238.
Rademaker M, Agnew K, Andrews M, Armour K, Baker C, Foley P, Frew J, Gebauer K, Gupta M, Kennedy D, Marshman G, Sullivan J. Psoriasis in those Planning a Family, Pregnant or Breastfeeding. The Australasian Psoriasis Collaboration. Australas J Dermatol. 2018;59:86-100. https://doi.org/10.1111/ajd.12641
Griffiths CE. Management of Psoriasis in Pregnancy: Time to Deliver? Br J Dermatol. 2010;163(2):235. https://doi.org/10.1111/j.1365-2133.2010.09925.x
Kurizky PS, Ferreira Cde C, Nogueira LS, Mota LM. Treatment of Psoriasis and Psoriatic Arthritis During Pregnancy and Breastfeeding. An Bras Dermatol. 2015;90(3):367-375. https://doi.org/10.1590/abd1806-4841.20153113
Cohen-Barak E, Nachum Z, Rozenman D, Ziv M. Pregnancy Outcomes in Women with Moderate-to-severe Psoriasis. J Eur Acad Dermatol Venereol. 2011;25(9):1041-1047. https://doi.org/10.1111/j.1468-3083.2010.03917.x
Bröms G, Haerskjold A, Granath F, Kieler H, Pedersen L, Berglind IA. Effect of Maternal Psoriasis on Pregnancy and Birth Outcomes: A Population-based Cohort Study from Denmark and Sweden. Acta Derm Venereol. 2018;98:728-734. https://doi.org/10.2340/00015555-2923
Bandoli G, Johnson DL, Jones KL, Lopez Jiminez J, Salas E, Mirrasoul N, Van Voorhees AS, Chambers CD. Potentially Modifiable Risk Factors for Adverse Pregnancy Outcomes in Women with Psoriasis. Br J Dermatol. 2010;163(2):334-339. https://doi.org/10.1111/j.1365-2133.2010.09899.x
Bobotsis R, Gulliver WP, Monaghan K, Lynde C, Fleming P. Psoriasis and Adverse Pregnancy Outcomes: A Systematic Review of Observational Studies. Br J Dermatol. 2016;175(3):464-472. https://doi.org/10.1111/bjd.14547
Ferreira C, Azevedo A, Nogueira M, Torres T. Management of Psoriasis in Pregnancy - A Review of the Evidence to Date. Drugs Context. 2020;9:2019-11-6. PMID: 32201494; PMCID: PMC7067229. https://doi.org/10.7573/dic.2019-11-6
Johansen CB, Egeberg A, Jimenez-Solem E, Skov L, Thomsen SF. Psoriasis and Adverse Pregnancy Outcomes: A Nationwide Case-control Study in 491,274 Women in Denmark. JAAD Int. 2022;7:146-155. https://doi.org/10.1016/j.jdin.2022.03.009
Albanova VI, Kalinina OV, Petrova SYu. The Use of Urea for Skin Barrier Correction. Vestnik dermatologii i venerologii. 2022;98(4):67-74. (In Russ.). https://doi.org/10.25208/vdv1329
Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of Topical Corticosteroids in Pregnancy. Cochrane Database Syst. Rev. 2015;26:CD007346. https://doi.org/10.1002/14651858.CD007346.pub3
Bae YS, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo B Jr, Kimball AB. National Psoriasis Foundation. Review of Treatment Options for Psoriasis in Pregnant or Lactating Women: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012 Sept;67(3):459-477. https://doi.org/10.1016/j.jaad.2011.07.039
Pan M, Heinecke G, Bernardo S, Tsui C, Levitt J. Urea: A Comprehensive Review of the Clinical Literature. Dermatol Online J. 2013;19(11):20392.
Final report of the safety assessment of Urea. Int J Toxicol. 2005;24(3):1-56. https://doi.org/10.1080/10915810500257097
Franssen ME, van der Wilt GJ, de Jong PC, Bos RP, Arnold WP. A retrospective study of the teratogenicity of dermatological coal tar products. Acta Derm Venereol. 1999;79(5):390-391. https://doi.org/10.1080/000155599750010373
Hoffman MB, Farhangian M, Feldman SR. Psoriasis during pregnancy: characteristics and important management recommendations. Expert Rev Clin Immunol. 2015 June;11(6):709-720. https://doi.org/10.1586/1744666X.2015.1037742
Albanova VI, Belousova TA, Guzev KS, Zhuchkov SA, Krutykh EG, Lavrik OI, Nozdrin VI, Nozdrin KV. Berestin. Dyogot’ beryozovyj. M.: Retinoids JSC; 2010. (In Russ.).
Albanova VI, Belousova TA. Naftalan Oil and its Use in Medicine. Almanac 27. Retinoids. 2007:27:29-35. (In Russ.).
Nozdrin VI, Yatskovsky AN, Polyachenko LN, Volkov YuT, Guzev KS, Subbotin SM, Fedotov EV. Study of Specific Types of Toxicity of Videstim Ointment in Experiment. Almanac 8. Retinoids. 2000;8:12-19. (In Russ.).
Butareva MM, Kobyatskaya EE, Metzger AV, Israelian ZE, Petrova SYu, Albanova VI, Nozdrin KV. Comparative Effectiveness of Creams with Different Urea Concentrations of the Urocrem Cosmetic Series for Skin Xerosis. Kosmetika i meditsina. 2023;4:30-37. (In Russ.).
Bangsgaard N, Rørbye C, Skov L. Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments. Am J Clin Dermatol. 2015;16(5):389-398. https://doi.org/10.1007/s40257-015-0137-5
Paziana K, Del Monaco M, Cardonick E, Moritz M, Keller M, Smith B, Coscia L, Armenti V. Ciclosporin use During Pregnancy. Drug Saf. 2013; 36(5):279-294. https://doi.org/10.1007/s40264-013-0034-x
Barenbrug L, Groen MT, Hoentjen F, van Drongelen J, Reek JMPAVD, Joosten I, de Jong EMGJ, van der Molen RG. Pregnancy and Neonatal Outcomes in Women with Immune Mediated Inflammatory Diseases Exposed to Anti-tumor Necrosis Factor-α During Pregnancy: A Systemic Review and Meta-analysis. J Autoimmun. 2021;122:102676. https://doi.org/10.1016/j.jaut.2021.102676
Mariette X, Förger F, Abraham B, Flynn AD, Moltó A, Flipo RM, van Tubergen A, Shaughnessy L, Simpson J, Teil M, Helmer E, Wang M, Chakravarty EF. Lack of Placental Transfer of Certolizumab Pegol During pregnancy: results from CRIB, a prospective, postmarketing, Pharmacokinetic Study. Ann Rheum Dis. 2018;77(2):228-233. https://doi.org/10.1136/annrheumdis-2017-212196
Soh MC, Moretto M. The Use of Biologics for Autoimmune Rheumatic Diseases in Fertility and Pregnancy. Obstet Med. 2020;13(1):5-13. https://doi.org/10.1177/1753495X19841799
Förger F. Treatment with Biologics During Pregnancy in Patients with Rheumatic Diseases. Reumatologia. 2017;55(2):57-58. https://doi.org/10.5114/reum.2017.67598
Komaki F, Komaki Y, Micic D, Ido A, Sakuraba A. Outcome of Pregnancy and Neonatal Complications with Anti-tumor Necrosis Factor-α Use in Females with Immune Mediated Diseases; A Systematic Review and Meta-analysis. J Autoimmun. 2017;76:38-52. https://doi.org/10.1016/j.jaut.2016.11.004
Clowse MEB, Scheuerle AE, Chambers C, Afzali A, Kimball AB, Cush JJ, Cooney M, Shaughnessy L, Vanderkelen M, Förger F. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database. Arthritis Rheumatol. 2018;70(9):1399-1407. https://doi.org/10.1002/art.40508